GERMANY - Bridgepoint acquires Dragenopharm
Bridgepoint has acquired a majority stake in generic drugs contract manufacturer Dragenopharm Apotheker Püschl GmbH for an undisclosed amount.
The company is headquartered in Tittmoning, Bavaria, and specialises in the production and packaging of solid dosage form and coating of tablets. Dragenopharm operates four manufacturing sites in Germany and currently has a portfolio of more than 1000 different products. In 2006 it is estimated to have produced more than five billion tablets, resulting in sales of approximately EUR 68m.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds
Back to Top








